

PRESS RELEASE  
13 June 2022 08:30:00 CEST

## Region Värmland introduces Stockholm3 in its organized program for prostate cancer screening

**Region Värmland was the first Swedish region to introduce organized prostate cancer screening in 2015. The program includes men in the age category 50-75 years. The region has now decided to include testing with Stockholm3, a blood test for early detection of aggressive prostate cancer.**

*"We are very proud and happy to be the first Swedish region to offer an organized screening program to all men at risk, similar to the screening for breast and cervical cancer that we offer women,"* says Göran Karlström, Chief Physician and Medical Director of Health and Healthcare services in Region Värmland.

*"It is very gratifying that Region Värmland introduces Stockholm3 for improved prostate cancer diagnostics, based on scientific studies. It provides great benefits for both men and healthcare in the region and we hope that in the long run, it will lead to general screening throughout the country",* says David Rosén, CEO of A3P Biomedical.

Earlier this year, a clinical study was published which Region Värmland conducted in collaboration with Karolinska Institutet with the support of the Swedish Prostate Cancer Association. The study, which includes 9,000 men, focused on finding men who have aggressive prostate cancer through better diagnostics and improved use of resources.

The results of the study show that the best strategy is to use Stockholm3 as a complement to today's analysis with PSA.

*"By using Stockholm3, we can better distinguish those men who need further testing, such as magnetic camera examination or biopsies",* says Mauritz Waldén, Med. Dr., Urologist and responsible for the research study.

Region Värmland has about 280,000 inhabitants, of which 50,000 are men in the age category 50-75 years, who have been offered organized PSA testing. The region now aims to reach the next level by using Stockholm3 at elevated PSA values.

**For additional information, please contact:**

---

David Rosen, CEO  
Telephone: +46 10 1823325  
Email: [david.rosen@a3p.com](mailto:david.rosen@a3p.com)

## About A3P Biomedical

---

**A3P Biomedical's** mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics. The company's lead product is **Stockholm3**, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit [www.a3p.com](http://www.a3p.com).

## About Stockholm3

---

Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer at an early stage. In clinical practice, Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).

Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from the latest pivotal study, a randomized study including 12,750 men, was published in The Lancet Oncology in 2021. Multiple studies have been published in high-impact journals, including a previous study with 58,000 men, published in The Lancet Oncology in 2015 (1).

Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Region Värmland has introduced general screening for prostate cancer with the help of Stockholm3 for men in the age category 50-75. Patients benefit from a more precise test (increasing sensitivity and specificity) and healthcare providers can reduce the direct costs by 17 to 28 percent (1).

### (1) Publications, results and clinical validation.

## About prostate cancer

---

Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. According to WHO, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported in 2020. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.

**Attachments**

---

[Region Värmland introduces Stockholm3 in its organized program for prostate cancer screening](#)